Investigating the SGF29/SAGA complex in regulation of normal and cancer stem cells
Grant Award Details
Grant Type:
Grant Number:
DISC0-15816
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$1,647,600
Status:
Pre-Active
Grant Application Details
Application Title:
Investigating the SGF29/SAGA complex in regulation of normal and cancer stem cells
Public Abstract:
Research Objective
This study will address gaps in our understanding of how normal and cancer stem cells differ in their epigenetic states, helping develop new cancer-stem-cell-targeting therapis.
Impact
The long-term impact of our studies is the understanding of mechnistic differences between normal and cancer stem cells and the development of new therapies.
Major Proposed Activities
This study will address gaps in our understanding of how normal and cancer stem cells differ in their epigenetic states, helping develop new cancer-stem-cell-targeting therapis.
Impact
The long-term impact of our studies is the understanding of mechnistic differences between normal and cancer stem cells and the development of new therapies.
Major Proposed Activities
- Evaluation of the role of SGF29 in normal hematopoiesis
- Evaluation of the role of SGF29 in LSC activity
- Preclinical evaluation of SGF29/KAT2A inhibitors in anti-LSC activity
Statement of Benefit to California:
The population > 60 years of age is expected to show an overall increase of 166% in the next 4-5 decades in California, with an anticipated increase in the rise of several cancers. AML incidence rises with age and most elderly patients succumb to the disease. Our studies, aimed at evaluating novel treatments for AML may help benefit patients diagnosed with AML. Our studies on novel agents may also bring economic benefit if novel drug candidates proceed to clinical translation from our studies.